Multidisciplinary management of gastric and gastroesophageal cancers

World Journal of Gastroenterology

Volumn 14, Issue 24, 2008, Pages 3773-3780

  Moehler, Markus ^a   Galle, Peter R ^a   Lyros, Orestis ^a   Gockel, Ines ^a   Lang, Hauke ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Adjuvant; Chemoradiation; Chemotherapy; Gastric cancer; Neoadjuvant

Indexed keywords

CETUXIMAB; CISPLATIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG EFFICACY; EDITORIAL; ENDOSCOPIC SURGERY; ESOPHAGUS CANCER; HUMAN; LAPAROSCOPY; LYMPHADENECTOMY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; SKIN DISEASE; STOMACH CANCER; SURVIVAL TIME; TOTAL STOMACH RESECTION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 54349128438     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.3773     Document Type: Editorial

References (59)

1. Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228: 449-461
2. Sasako M. Principles of surgical treatment for curable gastric cancer. J Clin Oncol 2003; 21: 274s-275s
3. Moehler M, Schimanski CC, Gockel I, Junginger T, Galle PR. (Neo)adjuvant strategies of advanced gastric carcinoma: time for a change? Dig Dis 2004; 22: 345-350
4. Sotiropoulos GC, Kaiser GM, Lang H, Treckmann J, Brokalaki El, Pottgen C, Gerken G, Paul A, Broelsch CE. Staging laparoscopy in gastric cancer. Eur J Med Res 2005; 10: 88-91
5. Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, Stein H, Lordick F, Link T, Schwaiger M, Siewert JR, Weber WA. Prediction or response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003; 21: 4604-4610
6. Pfau PR, Chak A. Endoscopic ultrasonography. Endoscopy 2002; 34: 21-28
7. Chen CH, Yang CC, Yeh YH. Preoperative staging of gastric cancer by endoscopic ultrasound: the prognostic usefulness of ascites detected by endoscopic ultrasound. J Clin Gastroenterol 2002; 35: 321-327
8. Denzer U, Hoffmann S, Helmreich-Becker I, Kauczor HU, Thelen M, Kanzler S, Galle PR, Lohse AW. Minilaparoscopy in the diagnosis of peritoneal tumor spread: prospective controlled comparison with computed tomography. Surg Endosc 2004; 18: 1067-1070
9. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, Bredenkamp R, Hofler H, Fink U, Peschel C, Schwaiger M, Siewert JR. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007; 8:797-805
10. Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 1999; 230: 170-178
11. Al-Refaie W, Pisters P, Chang G. 153Proximal versus total gastrectomy for proximal gastric cancer: A population-based appraisal. J Surg Res 2007; 137: 216-217
12. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, Mever S, Plukker JT, Van Elk P, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999; 340: 908-914
13. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M, Fayers P. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79: 1522-1530
14. Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg F, Songun I, Welvaart K, van Krieken JH, Merjer S, Plukker JT, van Elk PJ, Obertop H, Gouma DJ, van Lanschot JJ, laat CW, de Graat PW, von Meyenteldt MF, Tilanus H, Sasako M. Extended lymphnode dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Chin Oncol 2004; 22: 2069-2077
15. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka I, Kinoshita T, Arai K, Yamamura Y, Okajima K. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--japan Clinical Oncology Group study 9501. J. Clin Oncol 2004; 22: 2767-2773
16. Jansen EP, Boot H, Verheij M, van de Velde CJ. Optimal locoregional treatment in gastric cancer. J Clin Oncol 2005; 23: 4509-4517
17. Kooby DA, Suriawinata A, Klimstra DS, Brennan MF, Karpeh MS. Biologic predictors of survival in node-negative gastric cancer. Ann Surg 2003; 237: 828-835; discussion 835-837
18. Pech O, May A, Rabenstein T, Ell C. Endoscopic resection of early oesophageal cancer. Gut 2007; 56: 1625-1634
19. Hyung WJ, Cheong JH, Kim J, Chen J, Choi SH, Noh SH. Application of minimally invasive treatment for early gastric cancer. J Surg Oncol 2004; 85: 181-185; discussion 186
20. Falcone A. Future strategies and adjuvant treatment of gastric cancer. Ann Oncol 2003; 14 Suppl 2: ii45-ii47
21. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai, K. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;
22. De Vita F, Giuliani F, Orditura M, Maiello E, Galizia G, Di Martino N, Montemurro F, Carteni G, Manzione L, Romito S, Gebbia V, Ciardiello F, Catalano G, Colucci G. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol 2007; 18: 1354-1358
23. Hallissey MT, Dunn JA, Ward LC, Allum WH. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 1994; 343: 1309-1312
24. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Fstes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730
25. Park SH, Kim DY, Heo JS, Lim DH, Park CK, Lee KW, Choi SH, Sohn TS, Kim S, Noh JH, Kim YI, Park JO, Kim K, Kim WS, Jung CW, Im YH, Lee MH, Park K, Park CH, Kang WK. Postoperative chemoradiotherapy for gastric cancer. Ann Oncol 2003; 14: 1373-1377
26. Kelsen D. Neoadjuvant therapy for upper gastrointestinal tract cancers. Curr Opin Oncol 1996; 8: 321-328
27. Songun I, Keizer HJ, Hermans J, Klementschitsch P, de Vries JE, Wils JA, van der Bijl J, van Krieken JH, van de Velde CJ. Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG). Eur J Cancer 1999; 35: 558-562
28. Fujitani K, Ajani JA, Crane CH, Feig BW, Pisters PW, Janjan N, Walsh GL, Swisher SG, Vaporciyan AA, Rice D, Welch A, Baker J, Faust J, Mansfield PF. Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction. Ann Surg Oncol 2007; 14: 2010-2017
29. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in ciesophageal cancer: a randomised controlled trial. Lancet 2002; 359: 1727-1733
30. Allum WH, fogarty PJ, Stenning SP, Langley RL, NCRI Upper GI Cancer Clinical Studies Gioup. Long term results of the MRC OEO2 randomized trial of surgery with or without preoperative chemotherapy in resectable esophageal cancer. (Abstract, No. 9). 2008 Gastrointestinal Cancers Symposium; Jan 24. Available from: URL: http://www.asco.org/ASCO/ Abstracts+\26+Virtual+Meeting/ Abstracts?vmview-abst_detail_view&confJD=53&abstractlD=10652
31. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20
32. Boige V, Pignon J, Saint-Aubert B, Lasser P, Conroy T, Bouche O, Segol P, Bedenne L, Rougier P, Ychou M. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I, Vol 25, No. 18S (June 20 Supplement), 2007: 4510. Available from: URL: http://www.asco.org/ASCO/ Abstracts+%26+Virtual+Meeting/Abstracts?&vmview= abst_detail_view&conflD=47&abstractlD=33499
33. Lordick F, Stein HJ, Peschel C, Siewert JR. Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 2004; 91: 540-551
34. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339: 1979-1984
35. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996, 335: 462-467
36. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001; 19: 305-313
37. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D Adamo D, O'Reillv E, Tse A, Trocola R, Schwartz L. Capanu M, Schwartz GK, Kelsen DP. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24: 5201-5206
38. Stahl M, Walz MK, Stuschke M, Lehmann N, Seegenschmiedt MH, Riera Knorrenschild J, Langer P, Bieker M, Köniǵsrainer A, Budach W, Wilke H. Preoperative chemotherapy (CTX) versus preoperative chemoradiotherapy (CRTX) in locally advanced esophagogastric adenocarcinomas: First results of a randomized phase III trial. Journal of Clinical Oncology 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4511. Available from: URL: http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/ Abstracts?&vmview=abst_detail_view&conflD=47&abstractlD=31433
39. Lowy AM, Leach SD. Adjuvant/neoadjuvant chemoradiation for gastric and pancreatic cancer. Oncology (Williston Park) 1999; 13: 121-130
40. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680-2686
41. Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, Feig B, Myerson R, Nivers R, Cohen DS, Gunderson LL. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004; 22; 2774-2780
42. Ajani JA, Winter K, Okawara GS,.Donohue JH, Pisters W, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C, Rich TA. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 2006; 24: 3953-3958
43. Fu KK, Pajak TF, Frotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000, 48: 7-16
44. Hohler T, Mohler M. [New chemotherapeutic options in advanced gastric cancer] Onkologie 2003; 26 Suppl 7: 54-59
45. Mason KA, Hunter NR, Milas M, Abbruzzese JL, Milas L. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 1997; 3: 2431-2438
46. Ando N, Kato H, Shinoda M, Ozawa S, Shimizu H, Nakamura T, Yabuzaki Y, Aoyama N, Kurita A, Fukuda H. A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for localized squamous cell carcinoma of the thoracic esophagus (JCOG 9907). (Abstract, No.10). 2008 Gastrointestinal Cancers Symposium. Jan 24. Available from: URL: http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/ Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10425
47. Van Cutsem E, Van de Velde C, Roth A, Lordick F, Kohne CH, Cascinu S, Aapro M. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - gastrointestinal cancer group. Eur J Cancer 2008; 44: 182-194
48. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-2909
49. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997
50. Al-Batran SE, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S, Rummel MJ, Seipelt G, Rost A, Orth J, Knuth A, Jaeger E. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004; 22: 658-663
51. Moehler M, Eimermacher A, Siebler J, Hohler T, Wein A, Menges M, Flieger D, Junginger T, Geer T, Gracien E, Galle PR, Heike M. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer 2005; 92: 2122-2128
52. Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Cisar L, Wang K, Bugat R. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Abstract-No. 4003 ASCO Annual Meeting, 2005
53. Ajani JA, Lee FC, Singh DA, Haller DG, Lenz HJ, Benson AB 3rd, Yanagihara R, Phan AT, Yao JC, Strumberg D. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24: 663-667
54. Van Cutsem E, Dicato M, Arber N, Benson A, Cunningham D, Diaz-Rubio E, Glimelius B, Goldberg R, Haller D, Haustermans K, Koo-Kang Y, Labianca R, Lang I, Minsky B, Nordlinger B, Roth A, Rougier P, Schmoll HJ, Sobrero A, Tabernero J, Szawlowski A, van de Velde C. The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005. Ann Oncol 2006; 17 Suppl 6: vi13-vi18
55. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46
56. Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, Mutri V, Giaquinta S, Piana E, Martoni AA. Phase II study of cetuximab plus FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (FOLCETUX study): Preliminary results. (Abstract No. 4031). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 4031. Available from: URL: http://www. asco.org/ASCO/ Abstracts+%26+Virtual+Meeting/Abstracts ?&vmview=abst_detail_view&confID=40&abstractID=32624
57. Moehler MH, Trarbach T, Seufferlein T, Kubicka S, Lordick F, Geissler M, Daum S, Kanzler S, Galle P. AIO Gastric group. Cetuximab with irinotecan/Na-Fa/5-FU as first-line treatment in advanced gastric cancer: Preliminary results of a nonrandomised multi-centre AIO phase II study. (Abstract, No. 102). 2008 Gastrointestinal Cancers Symposium, Jan 24. Available from: URL: http://www.asco.org/ASCO/ Abstracts+%26+Virtual+Meeting/Abstracts?&v mview=abst_detail_view&confID=53&abstractID=10212
58. Lordick F, Lorenzen S, Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, Endlicher E, Röthling N, Fend F, Peschel C. Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4526. Available from: URL: http://www.asco.org/ASCO/ Abstracts+%26+Virtual+Meeting/Abstracts?&vmview =abst_detail_view&confID=47&abstractID=31912
59. Ajani J, Bekaii-Saab T, D'Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y. Gastric Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 2006; 4: 350-366